Becton, Dickinson and Company (NYSE:BDX) Now Covered by Analysts at Evercore

Equities researchers at Evercore started coverage on shares of Becton, Dickinson and Company (NYSE:BDX) in a note issued to investors on Monday. The firm set an “outperform” rating and a $180.00 price target on the medical instruments supplier’s stock. Evercore’s price target would indicate a potential upside of 20.02% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus boosted their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Wells Fargo & Company decreased their price target on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a report on Tuesday, February 10th. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Bank of America lifted their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Finally, Argus decreased their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Seven equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $188.43.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded up $0.66 during trading hours on Monday, reaching $149.97. 89,049 shares of the stock were exchanged, compared to its average volume of 2,751,457. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The firm has a 50 day simple moving average of $160.69 and a 200-day simple moving average of $181.92. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The stock has a market capitalization of $42.70 billion, a P/E ratio of 24.47, a P/E/G ratio of 10.65 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business had revenue of $4.49 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same period in the previous year, the business earned $3.43 EPS. The business’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.52 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. The trade was a 2.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 1,102 shares of company stock worth $198,909. Insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BDX. Activest Wealth Management boosted its stake in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 97 shares during the period. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. Steph & Co. boosted its stake in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares during the period. SHP Wealth Management acquired a new position in Becton, Dickinson and Company during the 4th quarter valued at about $26,000. Finally, Prosperity Bancshares Inc acquired a new position in Becton, Dickinson and Company during the 4th quarter valued at about $29,000. 86.97% of the stock is owned by institutional investors and hedge funds.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.